ReNAgade Therapeutics Announces Presentations at the ASGCT 27 th Annual Meeting
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024, in Baltimore, Maryland.
“We are excited to highlight foundational research and development advancements at ASGCT supported by our poster presentation illuminating ReNAgade’s continued work in validating our immune tropic LNP-based delivery systems in NHPs with broad potential applications in oncology and autoimmune diseases,” said Pete Smith, Ph.D., Chief Scientific Officer of ReNAgade. “Additionally, our oral presentation demonstrates a non-viral, all-RNA gene editing system enabling in vivo, exon-sized insertion and probable re-dosing with the goal of higher specificity and a better safety profile when used in the clinical setting. Together, these promising data are another important step in our efforts to innovate beyond the current limitations of RNA medicine.”
Key Highlights from the Abstracts:
- Employed a systematic barcoding screening approach to evaluate and identify engineered lipid nanoparticles (LNP) from a library of 200+ LNPs across multiple structural and chemically distinct classes of ionizable, helper, structural, and hydrophilic lipids. Lead LNP candidate demonstrated ~60% delivery efficiency in total splenic T cells and ~80% delivery efficiency in peripheral blood T cells in non-human primate models.
- Improved retron-mediated target insertion through a combination of retron reverse transcriptase (RT) engineering, non-coding RNA (ncRNA) minimization, chemical modification, and homology-dependent repair manipulation. Combination of retron system optimization and ncRNA engineering led to 2-fold higher 305 base pair insertion and ~40% editing efficiency in hematopoietic stem cells.
ASGCT Annual Meeting Presentation Details:
- TITLE: “Retron Mediated Exon-Sized Genome Insertion Using an All-RNA System”
SESSION TITLE: New Technologies for Gene Targeting and Gene Correction
PRESENTATION TYPE: Oral
ABSTRACT NUMBER: 14
PRESENTER: Inna Shcherbakova, Ph.D., Senior Director, Platform, ReNAgade Therapeutics
DATE AND TIME: Tuesday, May 7, 2024, from 2:15 p.m. - 3:30 p.m. ET
- TITLE: “Novel Immune Tropic LNP-Based mRNA Delivery in Non-Human Primates”
SESSION TITLE: Wednesday Posters: Other Nonviral Delivery
PRESENTATION TYPE: Poster
ABSTRACT NUMBER: 749
PRESENTER: Juliet Crabtree, Ph.D., Associate Principal Scientist, ReNAgade Therapeutics
DATE AND TIME: Wednesday, May 8, 2024, at 12:00 p.m. ET
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422868550/en/
Contact information
Investor Relations Contact:
Emily Brabbit, Argot Partners
(212) 600-1902
renagade@argotpartners.com
Media Relations Contact:
Sarah Sutton, Argot Partners
(212) 600-1902
renagade@argotpartners.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Breakthrough Discovery: British Explorer Andrew ‘Sandy’ Irvine’s Partial Remains Believed to Be Found on Mount Everest After 100 Years11.10.2024 08:00:00 CEST | Press Release
After 100 years of speculation surrounding his fate, the partial remains of Andrew Comyn “Sandy” Irvine are believed to have finally been discovered on Mount Everest. At age 22, Irvine vanished while attempting to conquer the world’s tallest peak on June 8, 1924, along with his climbing partner, renowned mountaineer George Mallory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010214459/en/ A sock embroidered with "A.C. Irvine", along with a boot, has been discovered on the Central Rongbuk Glacier below the North Face of Mount Everest by a team led by Jimmy Chin. This is the first possible proof of Irvine's death since disappearing during a 1924 expedition. (credit: Jimmy Chin) The discovery was made recently by a small team including National Geographic Explorer, photographer, Academy AwardⓇ-winning director and professional climber Jimmy Chin along with climbers and filmmakers Erich Roepke and Mark Fisher. What is beli
Vertex to Announce Third Quarter 2024 Financial Results on November 4 th10.10.2024 22:05:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2024 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, li
Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders10.10.2024 16:17:00 CEST | Press Release
Cognite,the Data and AI authority for industry, today announced the launch of Cognite Embedded. This new offering enables Original Equipment Manufacturers (OEMs) and Industrial Software Vendors (ISVs) to accelerate time to market, drastically reduce total cost of ownership, and future-proof their digital solutions with AI-ready architectures, all through Cognite’s leading industrial data platform, Cognite Data Fusion, and low-code industrial agent workbench, Cognite Atlas AI ®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009752580/en/ Cognite Launches "Cognite Embedded" to Accelerate Innovation for Equipment Manufacturers and Industrial Software Builders (Photo: Business Wire) Integrating and contextualizing data is often the biggest hurdle for OEMs and ISVs. Additionally, they need to onboard new customers and roll out data-driven solutions without the high costs associated with maintaining complex custom infrastructu
KAGA FEI Develops Ultra-small Bluetooth Low Energy Module Compatible with Bluetooth 6.010.10.2024 16:00:00 CEST | Press Release
KAGA FEI Co., Ltd., a global provider of leading short distance wireless modules, announced today the ES4L15BA1 Bluetooth Low Energy module. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010420482/en/ ES4L15BA1 (Photo: Business Wire) The module has a built-in antenna and has obtained various certifications. Consequently, it reduces the development time and certification costs for next-generation wireless IoT products such as IoT devices, small medical/healthcare products, and wearable devices that require a compact form factor, enabling faster time-to-market. The ES4L15BA1 also supports channel sounding for accurate distance measurement, providing further convenience for applications requiring reliable distance information or enhanced security based on device distance information, such as unlocking devices based on their proximity. Furthermore, it supports PSA*1 certification, making it easier to develop IoT devices that
Vespa.ai Announces Support for ColPali in Retrieval Augmented Generation (RAG)10.10.2024 15:00:00 CEST | Press Release
Vespa.ai, developer of the leading platform for AI applications including Retrieval-Augmented Generation (RAG), has today announced support for ColPali, a new open-source retrieval model for visually rich documents such as PDFs. ColPali enhances document retrieval by embedding entire rendered documents, including visual elements, into vector representations optimized for Large Language Models (LLMs). This reduces latency, improves accuracy, and enables more context-aware information retrieval, especially for visually rich content. By treating documents as visual entities rather than text, ColPali eliminates complex preprocessing, preserves visual context, and streamlines the RAG pipeline. Jon Bratseth, CEO and Founder, Vespa.ai: “With ColPali’s capabilities, combined with our scalable architecture and hybrid search, Vespa.ai delivers the fastest and most accurate solution for large-scale RAG and generative AI applications. Vespa is available as a service to simplify deployment further.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom